immunoglobulin heavy constant epsilon

Target id: 2741

Nomenclature: immunoglobulin heavy constant epsilon

Family: Immunoglobulins

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

   GtoImmuPdb view: OFF :     immunoglobulin heavy constant epsilon has curated GtoImmuPdb data

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 428 14q32.33 IGHE immunoglobulin heavy constant epsilon
Mouse - - 12 F1 Igh-7 immunoglobulin heavy chain 7 (heavy chain of IgE)
Previous and Unofficial Names
Ighe
Database Links
CATH/Gene3D
Ensembl Gene
Entrez Gene
GenitoUrinary Development Molecular Anatomy Project
Human Protein Atlas
KEGG Gene
OMIM
UniProtKB
Wikipedia
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  M1' peptide from IgE bound by humanized antibody 47H4 Fab
PDB Id:  3HR5
Ligand:  quilizumab
Resolution:  2.4Å
Species:  Mouse
References:  2

Download all structure-activity data for this target as a CSV file

Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Affinity Units Reference
ligelizumab Hs Binding 9.9 – 11.8 pKd 1,4
pKd 9.9 – 11.8 (Kd 1.39x10-10 – 1.47x10-12 M) [1,4]
Description: In vitro binding affinity
quilizumab Hs Binding 8.8 pKd 5
pKd 8.8 (Kd 1.5x10-9 M) [5]
omalizumab Hs Binding 7.6 – 8.2 pKd 1,3
pKd 8.2 (Kd 6.98x10-9 M) [1]
Description: In vitro binding affinity
pKd 7.6 (Kd 2.6x10-8 M) [3]
Description: F(ab) apparent binding affinity of e25 measured by surface plasmon resonance
Immunopharmacology Comments
IgE is being investigated as a molecular target in allergic inflammatory conditions such as asthma, allergic rhinitis and chronic spontaneous urticaria. One anti-IgE monoclonal, omalizumab, has already been approved for use in patients with asthma or chronic spontaneous urticaria. Omalizumab binds to circulating free IgE. The hunt for additional IgE-targeting antibodies is ongoing. Quilizumab, is one such investigational agent that targets the membrane bound IgE (mIgE) which forms the allergen-binding component of the B cell receptor.
Immuno Process Associations
Immuno Process:  Inflammation
Immuno Process ID:  2
Comment: 
GO Annotation:  Associated to GO processes
GO Processes:  phagocytosis, recognition (GO:0006910) IBA
phagocytosis, engulfment (GO:0006911) IBA
innate immune response (GO:0045087) IBA
References: 
Immuno Process:  Antigen presentation
Immuno Process ID:  3
Comment: 
GO Annotation:  Associated to GO processes
GO Processes:  phagocytosis, recognition (GO:0006910) IBA
phagocytosis, engulfment (GO:0006911) IBA
References: 
Immuno Process:  T cell (activation)
Immuno Process ID:  4
Comment: 
GO Annotation:  Associated to GO processes
GO Processes:  complement activation, classical pathway (GO:0006958) IBA
References: 
Immuno Process:  B cell (activation)
Immuno Process ID:  5
Comment: 
GO Annotation:  Associated to GO processes
GO Processes:  complement activation, classical pathway (GO:0006958) IBA
positive regulation of B cell activation (GO:0050871) IBA
References: 
Immuno Process:  Immune regulation
Immuno Process ID:  6
Comment: 
GO Annotation:  Associated to GO processes
GO Processes:  complement activation, classical pathway (GO:0006958) IBA
Fc-epsilon receptor signaling pathway (GO:0038095) TAS
B cell receptor signaling pathway (GO:0050853) IBA
positive regulation of B cell activation (GO:0050871) IBA
References: 
Immuno Process:  Cellular signalling
Immuno Process ID:  11
Comment: 
GO Annotation:  Associated to GO processes
GO Processes:  Fc-epsilon receptor signaling pathway (GO:0038095) TAS
B cell receptor signaling pathway (GO:0050853) IBA
positive regulation of B cell activation (GO:0050871) IBA
References: 

References

Show »

1. Arm JP, Bottoli I, Skerjanec A, Floch D, Groenewegen A, Maahs S, Owen CE, Jones I, Lowe PJ. (2014) Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin. Exp. Allergy44 (11): 1371-85. [PMID:25200415]

2. Brightbill HD, Jeet S, Lin Z, Yan D, Zhou M, Tan M, Nguyen A, Yeh S, Delarosa D, Leong SR et al.. (2010) Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice. J. Clin. Invest.120 (6): 2218-29. [PMID:20458139]

3. Lowman HB, Presta LG, Jardieu PM, Lowe J. (1999) Anti-IgE antibodies and methods of improving polypeptides. Patent number: US5994511. Assignee: Genentech, Inc.. Priority date: 02/07/1997. Publication date: 30/11/1999.

4. Singh S, Foster C, Wu H. (2009) High affinity anti-human IgE antibodies. Patent number: US7531169 B2. Assignee: Tanox, Inc.. Priority date: 01/02/2003. Publication date: 12/05/2009.

5. Wu L, Balazs M, Brightbill H, Chan A, Chen Y, Chuntharapai A, Dennis M, Wong T. (2011) Apoptotic anti-IgE antibodies. Patent number: US8071097 B2. Assignee: Genentech, Inc.. Priority date: 22/03/2007. Publication date: 06/12/2011.

How to cite this page

Immunoglobulins: immunoglobulin heavy constant epsilon. Last modified on 08/05/2017. Accessed on 21/10/2017. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2741.